| Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma NS Saba, D Liu, SEM Herman, C Underbayev, X Tian, D Behrend, ... Blood, The Journal of the American Society of Hematology 128 (1), 82-92, 2016 | 166 | 2016 |
| Interactions between ibrutinib and anti-CD20 antibodies: competing effects on the outcome of combination therapy M Skarzynski, CU Niemann, YS Lee, S Martyr, I Maric, D Salem, ... Clinical Cancer Research 22 (1), 86-95, 2016 | 101 | 2016 |
| Using prediction models to reduce persistent racial and ethnic disparities in the draft 2020 USPSTF lung cancer screening guidelines R Landy, CD Young, M Skarzynski, LC Cheung, CD Berg, MP Rivera, ... JNCI: Journal of the National Cancer Institute 113 (11), 1590-1594, 2021 | 94 | 2021 |
| Designing the Furin-Cleavable Linker in Recombinant Immunotoxins Based on Pseudomonas Exotoxin A JE Weldon, M Skarzynski, JA Therres, JR Ostovitz, H Zhou, RJ Kreitman, ... Bioconjugate chemistry 26 (6), 1120-1128, 2015 | 36 | 2015 |
| Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia B Vire, M Skarzynski, JD Thomas, CG Nelson, A David, G Aue, ... Cancer research 74 (24), 7510-7520, 2014 | 18 | 2014 |
| Health disparities in the immunoprevention of human papillomavirus infection and associated malignancies AH Bakir, M Skarzynski Frontiers in Public Health 3, 166952, 2015 | 16 | 2015 |
| SOLOMON: An ontology for sensory-onset, language-onset and motor-onset dementias M Skarzynski, A Craig, C Taswell 2015 IEEE International Conference on Bioinformatics and Biomedicine (BIBM …, 2015 | 10 | 2015 |
| Antibody targeting cell surface deposited complement protein C3d and use thereof AU Wiestner, MW Skarzynski, MA Lindorfer, RP Taylor, C Rader, B Vire US Patent 10,035,848, 2018 | 5 | 2018 |
| Anti-FGFR4 antibody drug conjugate for immune therapy of rhabdomyosarcoma and hepatocellular carcinoma A Cheuk, N Shivaprasad, M Skarzynski, S Baskar, P Azorsa, J Khan Cancer Research 78 (13_Supplement), 5618-5618, 2018 | 4 | 2018 |
| Antibody-based targeting of the cell surface receptor tyrosine kinase FGFR4 in rhabdomyosarcoma and other cancers M Skarzynski, N Shivaprasad, B Subramanian, D Azorsa, Z Zhu, ... Cancer Research 77 (13_Supplement), 693-693, 2017 | 3 | 2017 |
| Recalibration of a deep learning model for low-dose computed tomographic images to inform lung cancer screening intervals R Landy, VL Wang, DR Baldwin, PF Pinsky, LC Cheung, PE Castle, ... JAMA Network Open 6 (3), e233273-e233273, 2023 | 2 | 2023 |
| Hypothesis-exploring methods for automated meta-analyses of brain imaging literature SK Taswell, A Craig, D Leung, S Loh, M Skarzynski, S Gharabaghi, ... Proceedings Annual Meeting of the Western Region Society of Nuclear Medicine, 2015 | 2 | 2015 |
| Antibody targeting cell surface deposited complement protein C3d and use thereof AU Wiestner, MW Skarzynski, MA Lindorfer, RP Taylor, C Rader, B Vire US Patent 11,384,139, 2022 | | 2022 |
| MA05. 10 Performance of Draft 2020 USPSTF Lung-Cancer Screening Guidelines and Potential for use of Risk Models to Reduce Racial/Ethnic Disparities R Landy, C Young, M Skarzynski, L Cheung, C Berg, MP Rivera, ... Journal of Thoracic Oncology 16 (3), S151, 2021 | | 2021 |
| Abstract PO-247: Use of prediction models to reduce racial/ethnic disparities in eligibility for lung-cancer screening R Landy, CD Young, M Skarzynski, LC Cheung, CD Berg, MP Rivera, ... Cancer Epidemiology, Biomarkers & Prevention 29 (12_Supplement), PO-247-PO-247, 2020 | | 2020 |
| Abstract A110: Could use of individualized risk models mitigate health disparities in eligibility for lung cancer screening? H Katki, M Skarzynski, L Cheung, C Berg, A Chaturvedi, R Landy, ... Cancer Epidemiology, Biomarkers & Prevention 29 (6_Supplement_2), A110-A110, 2020 | | 2020 |
| Could Use of Individualized Risk Models Mitigate Health Disparities in Eligibility for Lung-Cancer Screening? R Landy, C Young, M Skarzynski, L Cheung, C Berg, HA Robbins, ... D15. ENVIRONMENTAL HEALTH DISPARITIES, A6224-A6224, 2020 | | 2020 |
| Targeting FGFR4 for rhabdomyosarcoma immunotherapy ATC Cheuk, N Shivaprasad, J Kumar, P Azorsa, M Skarzynski, S Baskar, ... EUROPEAN JOURNAL OF CANCER 103, E9-E10, 2018 | | 2018 |
| Potentiating immunotherapy by targeting complement deposited on cancer cell surfaces EJ Carstens, M Skarzynski, V Butera, M Lindorfer, B Vire, M Farooqui, ... Cancer Research 76 (14_Supplement), 1490-1490, 2016 | | 2016 |
| Monoclonal antibodies targeting cell surface deposited complement fragment C3d potentiate cancer immunotherapy and eliminate antigen loss variants M Skarzynski, M Lindorfer, V Butera, B Vire, M Farooqui, C Rader, ... Journal for ImmunoTherapy of Cancer 3, 1-1, 2015 | | 2015 |
Christoph RaderChief Technology Officer, Aethon Therapeutics, Inc.Verified email at aethontx.com
